Klow

KLOW is a research-grade blend of Semaglutide (GLP-1 receptor agonist, 2.4 mg/mL) + Cagrilintide (long-acting amylin analog, 1.2 mg/mL). The dual-receptor combination has been characterized in vitro across GLP-1R cAMP-accumulation assays and CTR/RAMP1-3 amylin-receptor binding panels — complementary appetite + glycemic-pathway readouts.

• GLP-1 receptor signaling
  cAMP accumulation in CHO cells stably expressing recombinant GLP-1R; β-arrestin recruitment kinetics.
  Working range: pM to nM range
• Amylin receptor binding
  Comparative binding panels across CTR/RAMP1-3 amylin receptor complexes vs native amylin.
  Working range: nM range
• Adipocyte energy expenditure
  Mitochondrial respiration (Seahorse XF) in 3T3-L1 differentiated adipocytes — paired vs single-agonist controls.
  Working range: 1 nM to 100 nM

Background: [[lyophilization]] · [[reconstitution]]

• Semaglutide (mono)
  Single-agonist baseline for receptor-bias and ligand-residency studies.
• Tirzepatide
  Comparator dual GLP-1/GIP agonist — complementary mechanism panel.
• Retatrutide
  Triple GLP-1/GIP/glucagon agonist — extends the comparator series.

1. Lau J, et al. (2015). Discovery of the once-weekly GLP-1 analogue Semaglutide. Journal of Medicinal Chemistry.
2. Lutz TA (2010). The role of amylin in the control of energy homeostasis. Endocrine Reviews.
3. Lau DCW, et al. (2021). Once-weekly cagrilintide for weight management. The Lancet.